Breast Cancer
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
- Details
ClinicalTrials.gov ID:
NCT06492616
Diagnosis Type:
NA
USOR Number:
- Address
,
P: